4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
News Jul 04, 2014
4SC AG has announced that Dr Erich Enghofer has joined 4SC in June 2014 in the newly created position of Executive Vice President Oncology and Haematology thus further strengthening the company's expertise.
The highly experienced pharma manager and oncology expert will primarily advance the strategic marketing of 4SC's main product resminostat in its further development toward market approval in the liver cancer indication.
In this connection, Dr Enghofer will further strengthen 4SC's positioning and products vis-à-vis potential pharmaceutical partners, strategic and clinical opinion leaders and investors, and also support the company in its partnering activities in the field of business development.
Dr Enghofer has more than 30 years of experience in the pharmaceutical industry with a focus on oncology, during which he held various management and executive positions at Bayer, Medac Schering Onkologie, Amgen, Cyanamid-Lederle and Klinge Pharma (now Astellas).
For the last nine years, he was head of the Business Unit Oncology (Haematology-Oncology since 2011) at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this function, he was instrumental, among other things, in the attainment of market approval of the small molecule anti-cancer drug sorafenib (Nexavar®) in the liver cancer indication and the drug's market success in Germany.
Dr Enghofer was a Board member of Deutsche Krebsgesellschaft (DKG, the German Cancer Society) until May 2014 and is a member of various high-profile professional organizations such as the German Association for Haematology and Oncology (DGHO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) and the American Association for the Advancement of Science (AAAS).
Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast expertise in the field of oncology, especially with the drug sorafenib for treating liver cancer, will further strengthen our team and is most welcome - especially for positioning our compound resminostat as a new potential liver cancer therapy and in our ongoing preparations for a Phase II trial in this indication. Dr Enghofer will also provide crucial support to 4SC in the expansion of a partner network to key opinion leaders and pharmaceutical companies, as well as in the business development process."
Dr Erich Enghofer commented: "I am very much looking forward to working in such a dynamic biotechnology company as 4SC, which has developed a promising and innovative approach for the liver cancer indication with resminostat. I have been following the company's activities and product developments, especially resminostat, for several years now. Liver cancer is the fifth most common type of cancer worldwide and the third most frequent tumour-related cause of death. The number of new cases has been rising sharply over the recent years, giving rise to a high unmet medical need. My goal is to make a contribution to attaining market approval for resminostat so as to make it available for patients as quickly as possible."
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Understanding the Cellular Systems that Hold Back the Spread of CancerNews
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.READ MORE
Comments | 0 ADD COMMENT
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018